Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SCYNEXIS’s clinical updates, royalty agreements, and dilution clauses across dozens of forms can feel like navigating a lab notebook written in legal code. Each 10-K details multi-arm Phase 3 trial data, while an 8-K may quietly announce a material safety issue or new partnership. Stock Titan surfaces every line the moment it hits EDGAR, so SCYNEXIS SEC filings are explained simply—no pharmacology degree required.
Our AI engine distills the 250-page SCYNEXIS annual report 10-K simplified, highlights cash runway assumptions, and flags risk disclosures about antifungal resistance. Need the latest SCYNEXIS quarterly earnings report 10-Q filing? We tag revenue from ibrexafungerp launches and compare R&D spend quarter-over-quarter. Curious about SCYNEXIS Form 4 insider transactions real-time? Receive instant alerts on executive stock movements, then dive into our charted trend analysis. From SCYNEXIS proxy statement executive compensation to every SCYNEXIS 8-K material events explained, you’ll know where trial milestones, ATM sales, or licensing royalties show up—and why they matter.
Investors use Stock Titan to:
- Track SCYNEXIS insider trading Form 4 transactions before FDA catalysts
- Compare drug-development costs via our SCYNEXIS earnings report filing analysis
- Save hours understanding SCYNEXIS SEC documents with AI through concise bullet summaries and red-flag alerts
SCYNEXIS, Inc. reported that the FDA lifted the clinical hold on ibrexafungerp on April 24, 2025, and dosing in the Phase 3 MARIO study resumed in May 2025, prompting the company to bill a $10.0 million development milestone to GSK in Q2 2025. The company is disputing GSK’s April 28, 2025 notice that purported to terminate the MARIO study and deny further milestone payments, including a $30.0 million milestone tied to study resumption.
Financially, SCYNEXIS recognized $1.364 million in license revenue for the quarter and reported a net loss of $6.885 million for Q2 2025 ($12.276 million year-to-date). Cash and investments totaled $46.5 million at June 30, 2025 (down from $75.1 million at year-end), the March 2019 convertible notes were repaid $14.0 million in March 2025, and the accumulated deficit was $388.8 million. The company received a Nasdaq deficiency notice on June 20, 2025 for a closing bid below $1.00 and has until December 17, 2025 to regain compliance. Ongoing securities class and derivative lawsuits remain pending.
SCYNEXIS (Nasdaq: SCYX) disclosed receipt of a Nasdaq bid-price deficiency notice on 20 Jun 2025 after its shares closed below $1.00 for 30 straight sessions.
The company has 180 days (until 17 Dec 2025) to lift the bid to at least $1 for 10 consecutive trading days. If unsuccessful, it may transfer to the Nasdaq Capital Market for another 180-day cure or face delisting, subject to appeal.
- Current Nasdaq Global Market listing remains unaffected.
- Management can pursue a reverse stock split or other actions to regain compliance.
- The notice heightens liquidity and funding risk and could deter institutional holders.
FAQ
What is the current stock price of Scynexis (SCYX)?
What is the market cap of Scynexis (SCYX)?
